FDA approves Halozyme’s VYVGART Hytrulo for CIDP treatment
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), co-formulated with ENHANZE, Halozyme’s proprietary recombinant human hyaluronidase enzyme (rHuPH20). This approval marks a new era for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP), introducing the […]